modelTechnetium99mtcNanocollo
Extends from Pharmacolibrary.Drugs.ATC.V.V09EA03.
Information
| name: | Technetium99mtcNanocolloid | |
| ATC code: | V09EA03 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 0.1 | mg |
| volume of distribution: | 0.15 | L |
| clearance: | 0.02 | L/h |
| other parameters in model implementation | ||
Technetium (99mTc) nanocolloid is a radiopharmaceutical agent primarily used for lymphoscintigraphy to identify sentinel lymph nodes, as well as for imaging the liver, spleen, and assessing bone marrow activity. It consists of technetium-99m labeled human serum albumin nanocolloid particles. The drug is approved and widely used for diagnostic imaging procedures, particularly in oncology for mapping lymph node drainage.
Pharmacokinetics
Pharmacokinetic parameters reported for adult patients undergoing sentinel lymph node imaging after subcutaneous or peritumoral administration.
References
Bourgeois, P (2002). Effects of age and lateralization on lymphoscintigraphic interpretation. Nuclear medicine communications 23(3) 257–260. DOI:10.1097/00006231-200203000-00009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11891484
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)